Last updated: February 15, 2026
What is the current market status for NDC 69097-0301?
NDC 69097-0301 corresponds to Emgality (galcanezumab-gnlm), a monoclonal antibody approved for migraine prevention and cluster headaches. It was approved by the FDA in September 2018. The drug targets calcitonin gene-related peptide (CGRP), a known mediator of migraine pathology.
Demand for migraine prophylactics has increased due to rising patient awareness and approval expansions. Emgality competes with other CGRP inhibitors, including erenumab, fremanezumab, and galcanezumab, which share similar indications.
How does the drug's market share compare to competitors?
| Drug |
Approval Date |
Annual Sales (2022) |
Market Share (Estimated, 2022) |
Key Competitors |
| Emgality (Gal-gnlm) |
September 2018 |
$460 million |
approx. 20-25% |
Aimovig (erenumab), Ajovy (fremanezumab), Vyepti (eptinezumab) |
| Aimovig |
May 2018 |
$1.1 billion |
approx. 40% |
- |
| Ajovy |
September 2018 |
$356 million |
approx. 10-15% |
- |
| Vyepti |
December 2019 |
$百 million |
niche below others |
- |
Note: Figures approximate, based on IQVIA data and press releases.
What are the key factors influencing Emgality’s pricing?
- Pricing per dose: Approximately $675 to $750.
- Dosing frequency: Monthly injections; some formulations allow bi-monthly dosing.
- Reimbursement landscape: Payers often prefer drugs with broader coverage and lower out-of-pocket costs.
- Competitive dynamics: The efficacy and safety profile influence pricing strategies. Emgality's unique indication for episodic and chronic cluster headaches adds market niche value.
What are the recent and projected sales trends?
Since its launch, Emgality has seen steady growth, but lagging behind Aimovig's higher sales. Large payer networks favor drugs with established efficacy profiles. Market penetration is gradually improving, contingent on prescriber familiarity and formulary inclusion.
Forecasts indicate a compound annual growth rate (CAGR) of approximately 8-10% over the next five years, driven by expanded indications and increased awareness. The global migraine therapeutics market is expected to reach $7.2 billion by 2028, with Emgality poised to maintain a significant share [2].
What are the main factors impacting price projections?
- Patent status: Expiry of key patents scheduled for 2027 could introduce biosimilar competition, likely decreasing prices by 2028.
- Regulatory changes: Approval for additional indications (e.g., chronic migraine prevention) can expand market share.
- Competitive entry: Biosimilars or new CGRP inhibitors could reduce prices, especially post-patent expiration.
- Market dynamics: Adoption rates and insurer formulary lists significantly affect actual sales prices and patient access.
What are the regulatory and patent timelines?
- Patent protections: The original patents for galcanezumab are set to expire around 2027. Patent litigations and potential extensions could alter this timeline.
- Regulatory submissions: The FDA approved the drug for episodic migraine in September 2018, and for chronic migraine in September 2020. Additional indications may be pursued based on ongoing clinical trials.
What is the outlook for drug pricing?
Current list prices hover around $675-$750 per dose. With patent protection until 2027, pricing remains stable, but market entry of biosimilars could lead to reductions of up to 30-50% post-expiration. Payer negotiations, formulary placement, and competitive launches are critical factors influencing actual transaction prices.
Summary of key data points
- List price: ~$700 per injection
- Approved indications: Episodic migraine, chronic migraine, and cluster headache
- Market share (2022): 20-25%
- Sales (2022): ~$460 million
- Patent expiry: 2027 (potential biosimilar entry)
Key Takeaways
- Emgality holds a niche within migraine prophylactics, competing primarily with Aimovig and Ajovy.
- Pricing is stable prior to patent expiration, with potential reductions after.
- Sales growth depends on expanded indications and market penetration.
- Patent expiry slated for 2027 presents significant price compression opportunities.
- Market dynamics favor biosimilar entry, likely reducing prices and expanding access.
FAQs
1. How does Emgality's pricing compare to other CGRP inhibitors?
Emgality's per-dose price is similar to Aimovig but slightly higher than Ajovy, reflecting differences in dosing frequency, manufacturer pricing strategies, and negotiation outcomes.
2. What is the impact of biosimilar competition on Emgality?
Biosimilar entry post-2027 could reduce prices by half, disrupting current revenue streams. Manufacturers may also offer lower-cost formulations to maintain market share.
3. Are there ongoing efforts to expand Emgality's indications?
Yes, clinical trials are underway for additional uses such as medication overuse headache and other migraine subtypes, which could increase sales and influence pricing strategies.
4. What is the outlook for global markets outside the US?
Europe and other regions are adopting Emgality, but pricing may vary driven by local approval processes and reimbursement policies. International patent statuses also impact competitive dynamics.
5. How do payer policies influence Emgality's pricing?
Insurers favor drugs with high efficacy and proven cost-effectiveness. Formulary inclusion and negotiated discounts influence actual patient access and net prices.
Sources:
[1] IQVIA, "Pharmaceutical Market Data," 2022.
[2] MarketWatch, "Migraine Therapeutics Market Forecast," 2023.
[3] FDA Drug Approval Database, 2018-2020.
